6780 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 21
Carroll et al.
(9) Mello, N. K.; Negus, S. S. Preclinical evaluation of pharmaco-
therapies for treatment of cocaine and opioid abuse using drug self-
administration procedures. Neuropsychopharmacology 1996, 14,
375–424.
(10) Rothman, R. B.; Glowa, J. R. A review of the effects of dopami-
nergic agents on humans, animals, and drug-seeking behavior, and
its implications for medication development. Mol. Neurobiol. 1995,
11, 1–19.
(11) Mishra, M.; Kolhatkar, R.; Zhen, J.; Parrington, I.; Reith, M. E.;
Dutta, A. K. Further structural optimization of cis-(6-benzhydryl-
piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane de-
rivatives by introducing an exocyclic hydroxyl group: interaction
with dopamine, serotonin, and norepinephrine transporters.
Bioorg. Med. Chem. 2008, 16, 2769–2778.
(31) Newton, T. F.; Roache, J. D.; De La Garza, R.; Fong, T.; Wallace,
C. L.; Li, S. H.; Elkashef, A.; Chiang, N.; Kahn, R. Bupropion
reduces methamphetamine-induced subjective effects and cue-
induced craving. Neuropsychopharmacology 2006, 31, 1537–1
544.
(32) Elkashef, A. M.; Rawson, R. A.; Anderson, A. L.; Li, S. H.;
Holmes, T.; Smith, E. V.; Chiang, N.; Kahn, R.; Vocci, F.; Ling,
W.; Pearce, V. J.; McCann, M.; Campbell, J.; Gorodetzky, C.;
Haning, W.; Carlton, B.; Mawhinney, J.; Weis, D. Bupropion for
the treatment of methamphetamine dependence. Neuropsycho-
pharmacology 2008, 33, 1162–1170.
(33) Shoptaw, S.; Heinzerling, K. G.; Rotheram-Fuller, E.; Steward, T.;
Wang, J.; N., S. A.; De La Garza, R.; Newton, T.; Ling, W.
Randomized, placebo-controlled trial of bupropion for the treat-
ment of methamphetamine dependence. Drug Alcohol Depend.
2008, 96, 222–232.
(12) Wilkes, S. The use of bupropion SR in cigarette smoking cessation.
Int. J. Chron. Obstruct. Pulmon. Dis. 2008, 3, 45–53.
(13) Tong, E. K.; Carmody, T. P.; Simon, J. A. Bupropion for smoking
cessation. A review. Comprehensive Therapy 2006, 32, 26–33.
(14) Hurt, R. D.; Sachs, D. P.; Glover, E. D.; Offord, K. P.; Johnston,
J. A.; Dale, L. C.; Khayrallah, M. A.; Schroeder, D. R.; Glover,
P. N.; Sullivan, C. R.; Croghan, I. T.; Sullivan, P. M. A comparison
of sustained-release bupropion and placebo for smoking cessation.
N. Engl. J. Med. 1997, 337, 1195–1202.
(15) Fava, M.; Rush, A. J.; Thase, M. E.; Clayton, A.; Stahl, S. M.;
Pradko, J. F.; Johnston, J. A. 15 years of clinical experience with
bupropion HCl: from bupropion to bupropion SR to bupropion
XL. Prim. Care Companion J. Clin. Psychiatry 2005, 7, 106–113.
(16) Ascher, J. A.; Cole, J. O.; Colin, J. N.; Feighner, J. P.; Ferris, R. M.;
Fibiger, H. C.; Golden, R. N.; Martin, P.; Potter, W. Z.; Richelson,
E.; et al. Bupropion: A review of its mechanism of antidepressant
activity. J. Clin. Psychiatry 1995, 56, 395–401.
(34) Zugibe, F. T.; Breithaupt, M.; Costello, J. Cardiotoxic mechanisms
and interrelationships of cocaine: including a single case depicting
several of these mechanisms. J. Clin. Forensic Med. 1998, 5, 140–
146.
(35) Volkow, N. D. Stimulant medications: how to minimize their
reinforcing effects? Am. J. Psychiatry 2006, 163, 359–361.
(36) Volkow, N. D.; Ding, Y. S.; Fowler, J. S.; Wang, G. J.; Logan, J.;
Gatley, J. S.; Dewey, S.; Ashby, C.; Liebermann, J.; Hitzemann, R.;
et al. Is methylphenidate like cocaine? Studies on their pharmaco-
kinetics and distribution in the human brain. Arch. Gen. Psychiatry
1995, 52, 456–463.
(37) Quinn, D. I.; Wodak, A.; Day, R. O. Pharmacokinetic and
pharmacodynamic principles of illicit drug use and treatment of
illicit drug users. Clin. Pharmacokinet. 1997, 33, 344–400.
(38) Gorelick, D. A. The rate hypothesis and agonist substitution
approaches to cocaine abuse treatment. Adv. Pharmacol. 1998, 42
(Catecholamines), 995-997.
(39) Mehta, N. B. The chemistry of bupropion. J. Clin. Psychiat. 1983,
45, 56–59.
(40) Chenard, B. L.; Bordner, J.; Butler, T. W.; Chambers, L. K.;
Collins, M. A.; De Costa, D. L.; Ducat, M. F.; Dumont, M. L.;
Fox, C. B.; Mena, E. E.; Menniti, F. S.; Nielsen, J.; Pagnozzi, M. J.;
Richter, K. E. G.; Ronau, R. T.; Shalaby, I. A.; Stemple, J. Z.;
White, W. F. (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-
(17) Dhillon, S.; Yang, L. P.; Curran, M. P. Bupropion: a review of its
use in the management of major depressive disorder. Drugs 2008,
68, 653–689.
(18) Ferris, R. M.; Cooper, B. R. Mechanism of antidepressant activity
of bupropion. J. Clin. Psychiatry Monogr. 1993, 11, 2–14.
(19) Cryan, J. F.; Dalvi, A.; Jin, S. H.; Hirsch, B. R.; Lucki, I.; Thomas,
S. A. Use of dopamine-beta-hydroxylase-deficient mice to deter-
mine the role of norepinephrine in the mechanism of action of
antidepressant drugs. J. Pharmacol. Exp. Ther. 2001, 298, 651–657.
(20) Li, S. X.; Perry, K. W.; Wong, D. T. Influence of fluoxetine on the
ability of bupropion to modulate extracellular dopamine and
norepinephrine concentrations in three mesocorticolimbic areas
of rats. Neuropharmacology 2002, 42, 181–190.
(21) Kelley, J. L.; Musso, D. L.; Boswell, G. E.; Soroko, F. E.; Cooper,
B. R. (2S,3S,5R)-2-(3,5-Difluorophenyl)-3,5-dimethyl-2-morpho-
linol: A novel antidepressant agent and selective inhibitor of
norepinephrine uptake. J. Med. Chem. 1996, 39, 347–349.
(22) Nielsen, J. A.; Shannon, N. J.; Bero, L.; Moore, K. E. Effects of
acute and chronic bupropion on locomotor activity and dopami-
nergic neurons. Pharmacol., Biochem. Behav. 1986, 24, 795–799.
(23) Nomikos, G. G.; Damsma, G.; Wenkstern, D.; Fibiger, H. C.
Effects of chronic bupropion on interstitial concentrations of
dopamine in rat nucleus accumbens and striatum. Neuropsycho-
pharmacology 1992, 7, 7–14.
phenylpiperidino)-1-propanol: A potent new neuroprotectant
which blocks N-methyl-D-aspartate responses. J. Med. Chem.
1995, 38, 3138–3145.
(41) Birch, S. F.; Dean, R. A.; Fidler, F. A.; Lowry, R. A. The
preparation of the C10 monocyclic aromatic hydrocarbons.
J. Am. Chem. Soc. 1949, 71, 1362–1369.
(42) Bailey, W. F.; Punzalan, E. R. Convenient general method for the
preparation of primary alkyllithiums by lithium-iodine exchange.
J. Org. Chem. 1990, 55, 5404–5406.
(43) Musso, D. L.; Mehta, N. B.; Soroko, F. E. Synthesis and evalua-
tion of the anticonvulsant activity of a series of 2-amino-1-phenyl-
1-propanols derived from the metabolites of the antidepressant
bupropion. Bioorg. Med. Chem. Lett. 1997, 7, 1–6.
(44) Foley, K. F.; Cozzi, N. V. Novel aminopropiophenones as poten-
tial antidepressants. Drug Develop. Res. 2003, 60, 252–260.
(45) Eshleman, A. J.; Carmolli, M.; Cumbay, M.; Martens, C. R.; Neve,
K. A.; Janowsky, A. Characteristics of drug interactions with
recombinant biogenic amine transporters expressed in the same
cell type. J. Pharmacol. Exp. Ther. 1999, 289, 877–885.
(46) Froimowitz, M.; Wu, K. M.; Moussa, A.; Haidar, R. M.; Jurayj, J.;
George, C.; Gardner, E. L. Slow-onset, long-duration 3-(30,4’-
dichlorophenyl)-1-indanamine monoamine reuptake blockers as
potential medications to treat cocaine abuse. J. Med. Chem. 2000,
43, 4981–4992.
(24) Jones, C. N.; Howard, J. L.; McBennett, S. T. Stimulus properties
of antidepressants in the rat. Psychopharmacology (Berl.) 1980, 67,
111–118.
(25) Lamb, R. J.; Griffiths, R. R. Self-administration in baboons and
the discriminative stimulus effects in rats of bupropion, nomifen-
sine, diclofensine and imipramine. Psychopharmacology (Berl.)
1990, 102, 183–190.
(26) Ortmann, R. The conditioned place preference paradigm in rats:
effect of bupropion. Life Sci. 1985, 37, 2021–2027.
(27) Tella, S. R.; Ladenheim, B.; Cadet, J. L. Differential regulation of
dopamine transporter after chronic self-administration of bupro-
pion and nomifensine. J. Pharmacol. Exp. Ther. 1997, 281, 508–
513.
(28) Spealman, R. D.; Madras, B. K.; Bergman, J. Effects of cocaine
and related drugs in nonhuman primates. II. Stimulant effects on
schedule-controlled behavior. J. Pharmacol. Exp. Ther. 1989, 251,
142–149.
(29) Margolin, A.; Kosten, T. R.; Avants, S. K.; Wilkins, J.; Ling, W.;
Beckson, M.; Arndt, I. O.; Cornish, J.; Ascher, J. A.; Li, S. H.; et al.
A multicenter trial of bupropion for cocaine dependence in metha-
done-maintained patients. Drug Alcohol Depend. 1995, 40, 125–
131.
(30) Poling, J.; Oliveto, A.; Petry, N.; Sofuoglu, M.; Gonsai, K.;
Gonzalez, G.; Martell, B.; Kosten, T. R. Six-month trial of
bupropion with contingency management for cocaine dependence
in a methadone-maintained population. Arch. Gen. Psychiatry
2006, 63, 219–228.
(47) Katz, J. L.; Agoston, G. E.; Alling, K. L.; Kline, R. H.; Forster,
M. J.; Woolverton, W. L.; Kopajtic, T. A.; Newman, A. H.
Dopamine transporter binding without cocaine-like behavioral
effects: synthesis and evaluation of benztropine analogs alone
and in combination with cocaine in rodents. Psychopharmacology
(Berl.) 2001, 154, 362–374.
(48) Gonzalez, L. A.; Gatch, M. B.; Taylor, C. M.; Bell-Horner, C. L.;
Forster, M. J.; Dillon, G. H. Carisoprodol-mediated modulation of
GABAA receptors: in vitro and in vivo studies. J. Pharmacol. Exp.
Ther. 2009, 329, 827–837.
(49) Carroll, F. I.; Fox, B. S.; Kuhar, M. J.; Howard, J. L.; Pollard,
G. T.; Schenk, S. Effects of dopamine transporter selective 3-
phenyltropane analogs on locomotor activity, drug discrimination,
and cocaine self-administration after oral administration. Eur. J.
Pharmacol. 2006, 553, 149–156.
(50) Gatch, M. B.; Taylor, C. M.; Flores, E.; Selvig, M.; Forster, M. J.
Effects of monoamine oxidase inhibitors on cocaine discrimination
in rats. Behav. Pharmacol. 2006, 17, 151–159.